Effects of spironolactone on systolic blood pressure in experimental diabetic rats

Kidney International

Volumn 57, Issue 5, 2000, Pages 2064-2071

  Liu, Yan Jun ^a   Nakagawa, Yuichi ^a   Toya, Kazuhiko ^a   Wang, Ying ^a   Saegusa, Hirokazu ^a   Nakanishi, Toshiki ^a   Ohzeki, Takehiko ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

11 hydroxysteroid dehydrogenase; Blood pressure; Diabetes mellitus; IDDM; Mineralocorticoid receptor

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; INSULIN; ISOENZYME; MESSENGER RNA; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG SCREENING; ENZYME ANALYSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RNA ANALYSIS; STREPTOZOCIN DIABETES; SYSTOLIC BLOOD PRESSURE;

EID: 0034062309     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00055.x     Document Type: Article

References (48)

1. 1. CHAPMAN KE, KOTELEVTSER YV, JAMIESON PM, WILLIAMS LJ, MULLINST JJ, SECKL JR: Tissue specific modulation of glucocorticoid action by the 11β-hydroxysteroid dehydrogenase. Biochem Soc Trans 25:583-587, 1997
2. 2. FUNDER JW, PEARCE PT, SMITH R, SMITH AI: Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585, 1988
3. 3. EDWARDS CR, STEWART PM, BURT D, BRETI L, MCINTYRE MA, SUTANTO WS, DE KLOET ER, MONDER C: Localization of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 2:986-989, 1988
4. 4. MONDER C, WHITE PC: 11β-hydroxysteroid dehydrogenase. Vitam Horm 47:187-271, 1993
5. 5. RUSVAJ E, NARAY-FEJFS-TOTH A: A new isoforms of 11β-hydroxysteroid dehydrogenase in aldosterone target cells. J Biol Chem 268:10717-10720, 1993
6. 6. PENNING TM: Molecular endocrinology of hydroxysteroid dehydrogenase. Endocr Rev 18:281-305, 1997
7. 7. TANNIN GM, AGARWAL AK, MONDER C, NEW MI, WHITE PC: The human gene for 11β-hydroxysteroid dehydrogenase: Structure, tissue distribution, and chromosomal localization. J Biol Chem 266:16653-16658, 1991
8. 8. MUNE T, ROGERSON FM, NIKKILA H, AGARWAL AK, WHITE PC: Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat Genet 10:394-399, 1995
9. 9. WHITE PC, MUNE T, ROGERSON FM, KAYES KM, AGARWAL AK: 11β-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralococorticoid excess. Pediatr Res 41:25-29, 1997
10. 10. LO YH, SHEFF MF, LATIF SA, RIBEIRO C, SILVER H, BREM AS, MORRIS DJ: Kidney 11β-HSD2 is inhibited by glycyrrhetinic acid-like factors in human urine. Hypertension 29(1 Pt 2):500-505, 1997
11. 11. ZHOU MY, GOMEZ-SANCHEZ EP, COX DL, COSBY D, GOMEZ-SANCHEZ CE: Cloning, expression, and tissue distribution of the rat nicotinamide adenine dinucleotide-dependent 11β-hydroxysteroid dehydrogenase. Endocrinology 136:3729-3734, 1995
12. 12. WALKER BR, CONNACHER AA, WEBB DJ, EDWARDS CR: Glucocorticoids and blood pressure: A role for the cortisol/cortisone shuttle in the control of vascular tone in man. Clin Sci 83:171-178, 1992
13. 13. ROCHA R, CHANDER PN, KHANNA K, ZUKERMAN A, STIER CT JR: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31(Pt 2):451-458, 1998
14. 14. SOUNESS GW, MORRIS DJ: 11α-and 11β-hydroxyprogesterone, potent inhibitors of 11β-hydroxysteroid dehydrogenase, possess hypertensinogenic activity in the rat. Hypertension 27(3 Pt 1):421-425, 1996
15. 15. GOMEZ-SANCHEZ EP, GOMEZ-SANCHEZ CE: Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol 263:E1125-E1130, 1992
16. 16. OVERDIEK HW, HERMENS WA, MERKUS FW: New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther 38:469-474, 1985
17. 17. SKLUTH HA, GUMS JG: Spironolactone: A re-examination. DICP 24:52-59, 1990
18. 18. ROURKE KA, BERGSTROM JM, LARSON IW, COLBY HD: Mechanism of action of spironolactone on cortisol production by guinea pig adrenocortical cells. Mol Cell Endocrinol 81:127-134, 1991
19. 19. SECKL JR: 11β-hydroxysteroid dehydrogenase isoforms and their implications for blood pressure regulation. Eur J Clin Invest 23:589-601, 1993
20. 20. FUNDER JW: Apparent mineralocorticoid excess. Endocrinol Metab Clin North Am 24:613-621, 1995
21. 21. EPSTEIN M, SOWERS JR: Diabetes mellitus and hypertension. Hypertension 19:403-418, 1992
22. 22. FELDT-RASMUSSEN B, MATHIESEN ER, DECKERT T, GIESE J, CHRISTENSEN NJ, BENT-HANSEN L, NIELSEN MD: Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30:610-617, 1987
23. 23. SCHADE DS, EATON RP: The controversy concerning counterregulatory hormone secretion: A hypothesis for the prevention of diabetic ketoacidosis? Diabetes 26:596-599, 1977
24. 24. RHEES RW, WILSON CT, HENINGER RW: Influence of streptozotocin diabetes and insulin therapy on plasma corticosterone levels in male rats. Horm Metab Res 15:353-354, 1983
25. 25. DE NICOLA AF, DE FRIDMAN OI, CASTILLO EG, FOGLIA VG: The influence of streptozotocin diabetes on adrenal function in male rats. Horm Metab Res 8:388-392, 1976
26. 26. HAYASHI M, KITAJIMA W, SARUTA T: Aldosterone responses to angiotensin II, adrenocorticotropin, and potassium in chronic experimental diabetes mellitus in rats. Endocrinology 115:2205-2209, 1984
27. 27. DEFRONZO RA: Hyperkalemia and hyporeninemic hypoaldosteronism. Kidney Int 17:118-134, 1980
28. +, free radicals, and vascular dysfunction in early diabetes mellitus. Diabetologia 40(Suppl):S115-S117, 1997
29. 29. WILLIAMSON JR, CHANG K, FRANGOS M, HASAN KS, IDO Y, KAWAMURA T, NYENGAARD JR, VAN DEN ENDEN M, KILO C, TILTON RG: Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 42:801-813, 1993
30. 30. LIU YJ, NAKAGAWA Y, OHZEKI T: Gene expression of 11β-hydroxysteroid dehydrogenase type 1 and type 2 in the kidneys of insulin-dependent diabetic rats. Hypertension 31:885-889, 1998
31. 31. HAYASHI M, SENBA S, SAITO I, KITAJIMA W, SARUTA T: Changes in blood pressure, urinary kallikrein, and urinary prostaglandin E2 in rats with streptozotocin-induced diabetes. Naunyn Schmiedebergs Arch Pharmacol 322:290-294, 1983
32. 32. MAJIMA M, MISOGAMI S, KURUBAYASHI Y, KATORI M, OH-ISHI S: Hypertension induced by a nonpressor dose of angiotensin II in kiniogen-deficient rats. Hypertension 24:111-119, 1994
33. 33. LOW SC, MOISAN MP, NOBLE JM, EDWARDS CRW, SECKL JR: Glucocorticoids regulate hippocampal 11β-hydroxysteroid dehydrogenase activity and gene expression in vivo in the rat. J Neuroendocrinol 6:285-290, 1994
34. 34. SOUNESS GW, LATIF SA, LAURENZO JL, MORRIS DJ: 11α-and 11β-hydroxyprogesterone, potent inhibitors of 11β-hydroxysteroid dehydrogenase (isoforms 1 and 2), confer marked mineralocorticoid activity on corticosterone in the ADX rat. Endocrinology 136:1809-1812, 1995
35. 35. LIU YJ, NAKAGAWA Y, TOYA K, OHZEKI T: Sex-specific effects of growth hormone on hepatic 11β-hydroxysteroid dehydrogenase activity and gene expression in hypothyroid rats. Life Sci 61:325-334, 1997
36. 36. LIU YJ, NAKAGAWA Y, TOYA K, SAEGUSA H, NASUDA K, ENDOH A, OHZEKI T: Effects of thyroid hormone (thyroxine) and testosterone on hepatic 11β-hydroxysteroid dehydrogenase mRNA and activity in pubertal hypothyroid male rats. Metab Clin Exp 47:474-477, 1998
37. 37. AGARWAL AK, MONDER C, ECKSTEIN B, WHITE PC: Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. J Biol Chem 264:18939-18943, 1989
38. 38. WHITE PC, MUNE T, AGARWAL AK: 11β-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18:135-156, 1997
39. 39. REBUFFAT P, BELLONI AS, MALENDOWICZ LK, MAZZOCCHI G, MENEGHELLI V, NUSSDORFER GG: Effects of streptozotocin-induced experimental diabetes on the morphology and function of the zona fasciculata of rat adrenal cortex. Virchows Arch B Cell Pathol 56:13-19, 1988
40. 40. SCHWARTZ MW, STRACK AM, DALLMAN MF: Evidence that elevated plasma corticosterone levels are the cause of reduced hypothalamic corticotrophin-releasing hormone gene expression in diabetes. Regul Pept 72:105-112, 1997
41. 41. MCEWEN BS, DE KLOET ER, ROSTENE W: Adrenal steroid receptors and actions in the nervous system. Physiol Rev 66:1121-1188, 1986
42. 42. BOHR DF: What makes the pressure go up? A hypothesis. Hypertension 3:160-165, 1981
43. 43. GOMEZ-SANCHEZ EP: What is the role of the central nervous system in mineralocorticoid hypertension? Am J Hypertens 4:374-381, 1991
44. 44. MONDER C, LAKSHMI V: Corticosteroid 11β-dehydrogenase of rat tissues: Immunological studies. Endocrinology 126:2435-2443, 1990
45. 45. VAN DEN BERG DT, DE KLOET ER, DE JONG W: Central effects of mineralocorticoid antagonist RU-28318 on blood pressure of DOCA-salt hypertensive rats. Am J Physiol 267:E927-E933, 1994
46. 46. NIKKILA H, TANNIN GM, NEW MI, TAYLOR NF, KALAITZOGLOU G, MONDER C, WHITE PC: Defects in the HSD11 gene encoding 11β-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency. J Clin Endocrinol Metab 77:687-691, 1993
47. 47. SASAKI S, BUNAG RD: Insulin reverses hypertension and hypothalamic depression in streptozotocin diabetic rats. Hypertension 5:34-40, 1983
48. 48. KAWASHIMA H, IGARASHI T, NAKAJIMA Y, AKIYAMA Y, USUKI K, OHTAKE S: Chronic hypertension induced by streptozotocin in rats. Naunyn Schmiedebergs Arch Pharmacol 305:123-126, 1978